Neurological and psychiatric side effects of cimetidine are reviewed in 47 cases from the literature, and 3 further cases are described. Confusion, psychomotor restlessness, hallucinations and disorientation, stupor and coma were the main features; some had convulsions and a few exhibited focal neurological deficits or neuropathies. The signs appeared within 2 days in almost half of the patients, and remitted in most within 2-3 days. Predisposing factors, of which more than one may be present, are advanced age, hepatic or renal dysfunction, or severe underlying disease. The 3 cases described were all old, one had cirrhosis with bleeding oesophageal varices, and one had renal failure with nephrotic syndrome and amyloidosis.
Introduction
Cimetidine, the histamine H2 receptor blocking agent, is widely used for the treatment of duodenal ulcer, and is also administered in peptic oesophagitis, hypersecretory disorders and in acute gastrointestinal bleeding. The drug is generally well tolerated in doses of 1000-1200 mg daily. However, many side effects have been described. The first case of cimetidineinduced mental confusion was reported by Grimson in 1977, but (Adler, Sadja and Wilets, 1980; Aelaney and Ravey, 1977; Agarwal 1978; Arneson, 1979; Atkinson, 1980 ; Bacigalupo, Van-Lint and Marmont, 1978; Bale, 1979; Barbier and Hirsch, 1978; Barnhart and Bowden, 1979; Basavaraju et al, 1980; Cumming and Forster, 1978; Delaunois, 1979; Edmonds, Ashford and Brenner, 1979; Grimson 1977; Jefferson, 1979; Johnson and Bailey, 1979; Kimelblatt, 1980; Kinell and Webb, 1979; Klotz and Key, 1978; Levine, 1978; McMillen, Ambis and Siegel, 1978; Menzies-Gow, 1977; Mogelnicki, Waller and Finlayson, 1979; Nelson, 1977; Petite and Bloch, 1978; Quap, 1978; Robinson and Mulligan, 1977; Schentag et al., 1979; Vickery, 1978 effects. In those cases in which the side effects appeared after increasing the dose of cimetidine the time at which side effects appeared was stated as from the day on which the dose was increased. In 50% neurotoxic effects were prominent within 48 hr.
The time until remission occurred was the interval from the day on which the dose was reduced or stopped until relief of symptoms occurred. Almost two-thirds had returned to normal within 2 days. In 5 patients reduction of the dose without stopping the cimetidine brought about relief of the side effects.
The main clinical manifestations were mental confusion (52%), stupor or coma (22%) and neurological abnormalities (16%) such as peripheral neuropathy and pyramidal signs. Psychiatric complications were found in 10o and included depression and paranoid states.
The possible risk factors for developing cimetidine-induced toxicity are analysed in Table 2 . Severe 
Discussion
The literature review indicated that of 50 patients showing neurotoxicity from cimetidine, about 40% were aged 65 years or over. This proportion of elderly patients is much higher than expected among all patients taking cimetidine. Extensive toxicological and pharmacological studies in animals have failed to detect cimetidine in the central nervous system, and neurotoxicity has not been noted (Brimblecombe & Duncan, 1977; Burland et al., 1979; Canavan & Briggs, 1977) . Studies in man, however, have shown that the drug may cross the blood brain barrier.
Schentag et al., (1979) found in 5 patients with severe mental confusion following cimetidine administration that measurable amounts were detectable in the cerebrospinal fluid (CSF). Levels higher than 0.8 mg/ml were considered toxic. In one other report of 2 patients with neurotoxicity, CSF cimetidine levels of 0-82 mg/ml and 0-76 mg/ml were found (Edmonds et al., 1979) . These findings suggest that the neurotoxic effect may occur because cimetidine is blockhg histamine H2 receptors in the brain.
There are a few factors which may contribute to the elevation of the CSF levels of cimetidine. High serum concentration is a possibility, which in 5 patients may have been due to treatment with over dosage of cimetidine. However, excessive dosage was without side effects in a few patients (Gill, 1978; Illingworth & Jarvie, 1979 (Luk, Luk and Hendrix, 1979) . Furthermore cimetidine itself reduces creatinine clearance, and thereby might potentiate its own effect by an increased serum half-life. In addition to this, patients with liver disease showed a CSF/serum cimetidine ratio higher than normal (>0.24) (Schentag et al., 1979) Amol/l-300 mg 4 times daily (Luk et al., 1979 ).
This review of 50 patients suggests that cimetidine may be neurotoxic, particularly in old age, in debilitated patients, and in patients with renal or hepatic failure. In all these conditions, patients may be more sensitive to mental changes. However, as cessation of cimetidine resulted in remission in all of the patients and in most of them within 48 hr, use of the drug is not contraindicated in these patients. It is, however, recommended to start treatment with reduced dosage, and to monitor neurological and mental status.
Although trials of a new antihistamine H2 receptor blocker ranitidine revealed few side effects (Walt et al., 1981) , avoidance of neurotoxicity in the presence of renal failure still demands a smaller total daily dose of ranitidine (Bories et al., 1980; Sharpe and Burland, 1980 
